Brief: Hansa Biopharma: Positive Results From Analysis From NICE-01 Trial Of HNSA-5487
07/10/2024 10:50
Oct 7 (Reuters) - Hansa Biopharma AB HNSA.ST :
* TODAY ANNOUNCED POSITIVE RESULTS FROM A 12-MONTH FOLLOW UP
ANALYSIS FROM NICE-01 TRIAL OF HNSA-5487
* IN NICE-01 TRIAL, HNSA-5487 DEMONSTRATED RAPID AND HIGHLY
ROBUST
REDUCTION OF IGG LEVELS BY MORE THAN 95% WITHIN FEW HOURS POST
TREATMENT
Source text for Eikon: ID:nPrex33gsa
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS